Zhengye Biotechnology Holding (ZYBT) Other Accumulated Expenses (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Other Accumulated Expenses for 3 consecutive years, with $4.6 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Other Accumulated Expenses rose 22546.36% year-over-year to $4.6 million in Q4 2025; TTM through Dec 2025 was $4.6 million, a 22546.36% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, up 23240.0% from the prior year.
• Other Accumulated Expenses was $4.6 million for Q4 2025 at Zhengye Biotechnology Holding, up from $4.6 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $4.6 million in Q4 2025 and troughed at $20325.5 in Q4 2024.
• A 3-year average of $3.4 million and a median of $4.5 million in 2023 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses plunged 99.53% in 2024 and surged 22546.36% in 2025, its largest moves.
• Over 3 years, Other Accumulated Expenses stood at $4.3 million in 2023, then sank by 99.53% to $20325.5 in 2024, then surged by 22546.36% to $4.6 million in 2025.
• The last three Other Accumulated Expenses figures came in at $4.6 million (Q4 2025), $4.6 million (Q2 2025), and $20325.5 (Q4 2024), per Business Quant data.